Ibogaine is neither explicitly scheduled nor formally regulated under Congolese national drug law, leaving it in a legal grey zone with no specific prohibitions or protections in place. Last verified: April 22, 2026.

Current Legal Status

The Democratic Republic of Congo (DRC) does not list ibogaine or its primary alkaloid ibogaine hydrochloride under any national controlled substances schedule. The country's principal pharmaceutical and narcotics framework is governed by Loi n° 18/030 du 13 décembre 2018 portant protection de la santé publique contre les méfaits de l'alcool et des substances psychoactives (Law No. 18/030 of December 13, 2018 on protecting public health against the harmful effects of alcohol and psychoactive substances) and related ministerial orders issued by the Ministère de la Santé Publique, Hygiène et Prévention (Ministry of Public Health, Hygiene and Prevention). Neither this law nor its implementing decrees enumerate ibogaine as a controlled or prohibited substance.

The DRC also operates within the framework of the United Nations Single Convention on Narcotic Drugs (1961), the Convention on Psychotropic Substances (1971), and the UN Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances (1988), to all of which it is a signatory. Ibogaine is not scheduled under any of these international conventions, meaning the DRC has no treaty obligation to control it. The country has not enacted supplementary legislation to bring ibogaine under domestic control.

Iboga (Tabernanthe iboga), the plant from which ibogaine is derived, holds deep cultural and spiritual significance in parts of Central Africa, including in communities within the DRC and neighboring Gabon and the Republic of Congo. The Bwiti spiritual tradition, which uses iboga sacramentally, has adherents across this region. There is no formal statutory religious carve-out for iboga use in DRC law, but traditional and ceremonial use is culturally embedded and has not historically been the target of enforcement action. The absence of scheduling effectively means such practices are not legally criminalized at the national level.

Key point: Ibogaine is unscheduled in the DRC. Its possession, use, or administration is not explicitly illegal under currently available national law. However, the absence of explicit legal prohibition is not equivalent to formal legal authorization or regulatory approval.

Treatment Centers

There are no formally registered or government-licensed ibogaine treatment clinics operating in the DRC in any internationally recognized sense. The country's healthcare infrastructure faces severe systemic challenges — including chronic underfunding, limited specialist capacity, and ongoing humanitarian crises in eastern provinces — that make the development of a regulated ibogaine treatment sector extremely unlikely in the near term.

Iboga is administered within traditional Bwiti ceremonies in parts of the country, but these are spiritual and cultural practices rather than medical treatment centers. These settings do not operate under clinical oversight, do not maintain medical screening protocols, and should not be equated with the structured ibogaine treatment facilities found in countries such as Mexico, Portugal, or South Africa.

For a full directory of legitimate, medically supervised ibogaine treatment centers globally, see our ibogaine clinic directory.

How People Access Ibogaine in the Democratic Republic of Congo

Access to ibogaine in the DRC occurs through two primary channels, neither of which involves formal medical supervision:

  • Traditional Bwiti ceremonies: Communities in parts of the DRC with Bwiti cultural heritage administer iboga root bark as part of initiation rites and healing ceremonies. These are conducted by trained nganga (traditional healers or spiritual leaders) according to established ritual protocols. Doses used in these contexts can be very high and sessions can last 24–48 hours or longer.
  • Unregulated personal procurement: Some individuals seeking ibogaine for purposes such as addiction interruption obtain it through informal networks, including cross-border sources from Gabon or Cameroon, where Tabernanthe iboga grows natively and where the Bwiti tradition is more formally recognized. There is no pharmacy-dispensed ibogaine in the DRC and no clinical supply chain.
Important: Ibogaine carries significant cardiac risks, including QT interval prolongation that can lead to fatal arrhythmias. Access outside of medically supervised settings — with pre-screening EKG, contraindication checks, and emergency response capability — carries serious risks of death. This information is factual and does not constitute a recommendation to seek ibogaine through any channel.

Recent Legal Developments

No legislative developments specifically addressing ibogaine have been identified in the DRC within the past two years. The country's legislative agenda has been dominated by security, electoral, and humanitarian priorities. There has been no reported parliamentary debate, ministerial order, or regulatory consultation regarding ibogaine scheduling or clinical authorization.

Regionally, Gabon — where the Bwiti tradition and iboga are formally recognized as a national cultural heritage — formally listed Tabernanthe iboga as a protected plant species and a national heritage plant. This development has not prompted corresponding legislative action in the DRC, though it reflects a broader Central African recognition of iboga's cultural significance.

International bodies including the Commission on Narcotic Drugs (CND) have not moved to schedule ibogaine under UN conventions, which removes one of the most common external pressures on member states to enact domestic controls. This status is unlikely to change rapidly, though monitoring remains important.

Risks of Seeking Treatment in the Democratic Republic of Congo

Individuals considering ibogaine access in the DRC should be aware of the following risk factors:

  • No medical oversight: There are no licensed medical ibogaine providers in the DRC. Traditional Bwiti contexts do not include cardiac monitoring, medication screening, or emergency medical intervention capacity. This represents the highest-risk environment for ibogaine administration.
  • No quality control: Iboga root bark or extracts obtained outside of pharmaceutical supply chains have no standardized potency or purity verification. Alkaloid content in raw plant material varies significantly, making dose titration unreliable.
  • Healthcare infrastructure limitations: In the event of a medical emergency during or after ibogaine administration, access to advanced cardiac care, intensive care units, or defibrillation is severely limited across most of the DRC, including in Kinshasa. Response times and resource availability are not comparable to settings where regulated ibogaine therapy is practiced.
  • Security environment: Large areas of eastern DRC remain affected by armed conflict and humanitarian emergency conditions. Travel to or within the country for the purpose of seeking any treatment carries substantial physical safety risks independent of ibogaine itself.
  • Legal ambiguity: While ibogaine is not scheduled, legal frameworks in the DRC can be applied inconsistently. Foreigners in particular may face unpredictable interactions with law enforcement even where no specific law is violated.
  • No legal recourse: In the absence of a regulated treatment framework, individuals who experience harm have no formal legal or regulatory mechanism for complaint, redress, or accountability against providers.

Frequently Asked Questions

No. Ibogaine is not listed as a controlled or prohibited substance under current DRC national drug law, including Law No. 18/030 of 2018 and its implementing decrees. It is also not scheduled under the UN drug conventions to which the DRC is a party. However, the absence of explicit prohibition does not constitute formal legal authorization. The legal status is best described as unscheduled and unregulated.
The Bwiti spiritual tradition is practiced by communities in parts of the DRC, particularly those with cultural ties to Gabon and the Republic of Congo. There is no statute explicitly banning Bwiti ceremonies or the ceremonial use of iboga root bark. Because iboga and ibogaine are not scheduled substances under DRC law, their use in traditional ceremonial contexts is not a named criminal offense at the national level. However, there is no specific statutory protection either, unlike in Gabon where iboga has been formally recognized as a national heritage plant.
No. There are no formally registered, medically supervised ibogaine treatment clinics operating in the DRC. Iboga is administered in traditional Bwiti ceremonial settings in parts of the country, but these are not medical treatment centers and do not provide the clinical screening, monitoring, or emergency response infrastructure required for safe ibogaine administration. For medically supervised options, consult the ibogaine clinic directory.
Because ibogaine is not a scheduled substance in the DRC, there is no national law specifically prohibiting a foreigner from possessing or using it within the country. However, the DRC is an extremely challenging destination for medical travel due to healthcare infrastructure limitations, security conditions in many regions, inconsistent law enforcement, and the absence of regulated ibogaine providers. The practical and safety risks of doing so are very high and entirely separate from the question of legal status. Consulting a licensed attorney familiar with DRC law before making any such decisions is strongly advised.
It is theoretically possible for the DRC to add ibogaine to a national controlled substances schedule via ministerial order or parliamentary legislation. In practice, this appears unlikely in the near term given that ibogaine is not internationally scheduled by the UN, there is no domestic political pressure to control it, and it carries cultural significance in the broader region. Monitoring updates from the Ministère de la Santé Publique and the Commission on Narcotic Drugs is advisable for anyone with ongoing interest in this topic.
The primary risks include: the complete absence of medically supervised ibogaine providers with cardiac monitoring capability; very limited access to emergency cardiac care if a life-threatening arrhythmia occurs; no quality control or standardized dosing for traditionally prepared iboga; ongoing armed conflict and humanitarian crisis conditions in large parts of the country; and no legal or regulatory accountability framework if harm occurs. Ibogaine has a narrow therapeutic window and requires pre-treatment medical screening — risks are substantially elevated without it.

Informational only. Not legal advice. Laws change. Verify with a licensed attorney before making any decisions.